Recent U.S. Food and Drug Administration Labeling Changes for Hydroxyethyl Starch Products Due to Concerns about Mortality, Kidney Injury, and Excess Bleeding-Reference-Cited by-同舟云学术

Recent U.S. Food and Drug Administration Labeling Changes for Hydroxyethyl Starch Products Due to Concerns about Mortality, Kidney Injury, and Excess Bleeding

Published:2022-03-08 Issue:5 Volume:136 Page:868-870
ISSN:0003-3022
Container-title:Anesthesiology
language:en
Short-container-title:

Author:

Landow Laurence¹,Wei Shaokui,Song Linye,Goud Ravi,Cooper Katherine

Affiliation:

1. U.S. Food and Drug Administration, Silver Spring, Maryland (L.L.). laurence.landow@fda.hhs.gov

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine

Link

https://pubs.asahq.org/anesthesiology/article-pdf/136/5/868/669306/20220500.0-00034.pdf

Reference10 articles.

1. Postoperative renal replacement therapy after hydroxyethyl starch infusion: A meta-analysis of randomized trials.;Wilkes;Neth J Crit Care,2014

2. Effect of hydroxyethyl starch on outcomes in high-risk vascular surgery patients: A retrospective analysis.;Green;J Cardiothorac Vasc Anesth,2016

3. The risk of acute kidney injury from fluid restriction and hydroxyethyl starch in thoracic surgery.;Ahn;Anesth Analg,2016

4. Effect of hydroxyethyl starch on postoperative kidney function in patients having noncardiac surgery.;Kashy;Anesthesiology,2014

5. Hydroxyethyl starch 130/0.4 and the risk of acute kidney injury after cardiopulmonary bypass: A single-center retrospective study.;Lagny;J Cardiothorac Vasc Anesth,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Goal-Directed Therapy in Liver Surgery;Current Anesthesiology Reports;2024-02-23